Piper Sandler lowered the firm’s price target on Inozyme (INZY) to $30 from $43 and keeps an Overweight rating on the shares following a positive interim update from the Phase 1b ENERGY 1 study of INZ-701 in ENPP1-deficient infants showing reduced mortality and prevention of cardiovascular complications and rickets, two drivers of morbidity and mortality in this severe disease. The firm also gained clarity on pivotal trial planning in ABCC6, where the company is planning to run the ASPIRE trial starting in early 2026 with a 2-year, event-driven composite endpoint. Although this pushes timelines back, Piper views this clarity as removing a key overhang for the company.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme price target lowered to $11 from $14 at Wells Fargo
- Inozyme price target raised to $16 from $14 at H.C. Wainwright
- Inozyme Pharma Advances with Promising Trial Results
- Inozyme announces interim data from its ENERGY 1 trial, EAP on INZ-701
- Inozyme initiated with an Outperform at Raymond James